Sacituzumab tirumotecan improves survival in advanced endometrial cancer trial

A phase 3 international clinical trial has demonstrated that the antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) significantly improves survival rates for patients with advanced or recurrent endometrial cancer. The study, presented at the European Society for Medical Oncology (ESMO) congress and published in ‘The Lancet’, focused on patients who had previously undergone platinum-based chemotherapy and PD-1 or PD-L1 immunotherapy.

Results showed a median overall survival of 19.0 months for the sac-TMT group, compared to 12.1 months for the chemotherapy group, representing a 32% reduction in the relative risk of death. Additionally, median progression-free survival was 7.2 months with the targeted drug versus 3.9 months with standard chemotherapy, a 41% reduction in the risk of disease progression or death.

Sac-TMT works by targeting the TROP2 protein on cancer cells to deliver a therapeutic payload. While the drug showed a higher tumor response rate of 35.1% compared to 17.3% in the chemotherapy group, serious side effects were noted. Grade 3 or higher treatment-related side effects occurred in 54.4% of the sac-TMT group, including low blood counts, mouth inflammation, and eye symptoms.